Head-To-Head Survey: Auris Medical (EARS) & Its Peers
Auris Medical (NASDAQ: EARS) is one of 286 publicly-traded companies in the “Bio Therapeutic Drugs” industry, but how does it contrast to its competitors? We will compare Auris Medical to similar businesses based on the strength of its risk, dividends, earnings, institutional ownership, valuation, analyst recommendations and profitability.
Volatility and Risk
Auris Medical has a beta of 0.59, meaning that its stock price is 41% less volatile than the S&P 500. Comparatively, Auris Medical’s competitors have a beta of 5.98, meaning that their average stock price is 498% more volatile than the S&P 500.
This table compares Auris Medical and its competitors top-line revenue, earnings per share (EPS) and valuation.
|Gross Revenue||Net Income||Price/Earnings Ratio|
|Auris Medical||N/A||-$31.13 million||-0.71|
|Auris Medical Competitors||$284.49 million||$34.10 million||71.78|
Auris Medical’s competitors have higher revenue and earnings than Auris Medical. Auris Medical is trading at a lower price-to-earnings ratio than its competitors, indicating that it is currently more affordable than other companies in its industry.
Insider & Institutional Ownership
25.2% of Auris Medical shares are owned by institutional investors. Comparatively, 50.1% of shares of all “Bio Therapeutic Drugs” companies are owned by institutional investors. 17.3% of shares of all “Bio Therapeutic Drugs” companies are owned by company insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a stock will outperform the market over the long term.
This table compares Auris Medical and its competitors’ net margins, return on equity and return on assets.
|Net Margins||Return on Equity||Return on Assets|
|Auris Medical Competitors||-5,310.77%||-218.27%||-39.48%|
This is a breakdown of recent recommendations for Auris Medical and its competitors, as provided by MarketBeat.com.
|Sell Ratings||Hold Ratings||Buy Ratings||Strong Buy Ratings||Rating Score|
|Auris Medical Competitors||877||3245||11730||233||2.70|
Auris Medical presently has a consensus price target of $4.50, suggesting a potential upside of 878.26%. As a group, “Bio Therapeutic Drugs” companies have a potential upside of 46.35%. Given Auris Medical’s stronger consensus rating and higher probable upside, equities analysts clearly believe Auris Medical is more favorable than its competitors.
Auris Medical competitors beat Auris Medical on 8 of the 12 factors compared.
Auris Medical Company Profile
Auris Medical Holding AG is a holding and clinical-stage biopharmaceutical company focused on the development of products for the treatment of inner ear disorders. Its advanced product candidate, AM-101, is in Phase III clinical development for acute inner ear tinnitus under a special protocol assessment (SPA) from the United States Food and Drug Administration. Its second product candidate, AM-111, is being developed for the treatment of acute sensorineural hearing loss (ASNHL). It intends to conduct over two pivotal Phase III trials in the treatment of idiopathic sudden SNHL (ISSNHL), titled Acute Inner Ear Hearing Loss (HEALOS) and Acute Sudden Sensorineural Hearing Loss Treatment (ASSENT). AM-111 received orphan drug designation for the treatment of ASNHL from the United States Food and Drug Administration, and the European Union agency. It intends to conduct a Phase II trial in the treatment of surgery-induced hearing loss (REACH).
Receive News & Ratings for Auris Medical Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Auris Medical and related companies with MarketBeat.com's FREE daily email newsletter.